Pacira BioSciences (PCRX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Pacira BioSciences (PCRX) is Neutral.

The composite score behind that read is +0.18, weighing +0.36 of bullish evidence against -0.20 bearish.

Pacira BioSciences last closed at $36.31, -0.22% on the session.

Against the IVW growth benchmark the position is -1.02% over the forecast window.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

Pacira BioSciences has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Pacira BioSciences in the 6th percentile on valuation and the 43rd percentile on return on equity, where 100 is best.

Pacira BioSciences is classified under Health Care / Pharmaceuticals, with a market capitalisation of $1.45B.

StockMap tracks Pacira BioSciences as the 52nd largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Pacira BioSciences ranks 20th of 151 in the group, against a group median of -0.08.